Randomized, Double-blind, Placebo Controlled, Crossover Clinical Study to Analyse the Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function
Phase of Trial: Phase III
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
- 16 Mar 2016 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
- 18 Dec 2015 Planned end date changed from 1 Nov 2016 to 1 Jun 2016, as reported by ClinicalTrials.gov.